Judge Signals Doubt on AstraZeneca’s Harm in Drug Price Program

Harm to AstraZeneca caused by a government price-setting program and the administration’s implementation guidance is painted out vaguely, a district court judge told the diabetes drugmaker during an oral argument Wednesday.

Chief District Judge Colm F. Connolly for the US District Court for the District of Delaware repeatedly asked AstraZeneca what harm it will face from the US government’s Medicare drug price negotiation program.

AstraZeneca PLC is challenging the drug pricing program authorized by the 2022 Inflation Reduction Act that allows the government to set prices on some of the costliest drugs Medicare covers. AstraZeneca’s Farxiga, used to treat Type ...